ARTICLE SUMMARY:
Inivata’s “liquid biopsy” technology addresses the need for noninvasive clinical genomic tests that have both broad coverage of genes and high sensitivity, enabling it to identify de novo rare cancer mutations by screening entire genes and cost-effectively track tumor burden over time in blood.
Many companies are vying to build the most sensitive, specific, and fastest platform for noninvasive diagnosis and monitoring of cancer. It’s a hot area of research, as standard prognostic markers for cancer, based on tissue biopsy, are hard to access.
